General Patterns of Candida susceptibility to antifungal agents:
fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B,
flucytosine, candins
C. albicans: S to all
C. tropicalis: S to all
C. parapsilosis: S to all except S-R for candins
C. lusitaniae: S to all except S-R for amphotericin B
C. glabrata: S to flucytosine/candins; S-I to ampho B; S-DD to R for all others
C. krusei: S to voriconazole/posaconazole/candins; S-I to ampho B; S-DD to R for itraconazole; I-R for
flucytosine; R for fluconazole
S = sensitivity, I = intermediate, R = resistance, S-DD = susceptible dose dependent
Strength of Recommendation and Evidence Quality
Strength
Definition
A
Good evidence for or against a recommendation
B
Moderate evidence for or against a recommendation
C
Poor evidence to support a recommendation
Quality
Definition
I
Evidence from ≥ 1 randomized, controlled trial
II
Evidence from ≥ 1 clinical trial, without randomization; from cohort or
case-controlled analytic studies (preferably from > 1 center); from multiple
time-series; or dramatic results from uncontrolled experiments
III
Opinions of respected authorities, based on experience, descriptive studies,
or reports of expert committees
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient care.
It focuses on the needs of primary care practice, but also is applicable to providers at all levels.
This Guideline should not be considered exclusive of other methods of care reasonably directed at
obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must
be made by the clinician after consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
5740 Executive Drive Suite 220
Baltimore, MD 21228
TEL: 410-869-3332 • FAX: 410-744-2150
For additional copies: orders@GuidelineCentral.com
Copyright © 2010 All rights reserved
